Show simple item record

dc.contributor.authorDowney, Laura
dc.contributor.authorArnhold, Shana
dc.date.accessioned2007-08-20T14:32:33Z
dc.date.available2007-08-20T14:32:33Z
dc.date.issued2007-04-27
dc.identifier.citationDowney, Laura & Arnhold, Shana. (2007). A pilot study and retrospective chart review comparing adalimumab, infliximab, and etanercept in patients with active rheumatoid arthritis. In Proceedings : 3rd Annual Symposium : Graduate Research and Scholarly Projects. Wichita, KS : Wichita State University, p.37-38en
dc.identifier.urihttp://hdl.handle.net/10057/690
dc.descriptionPaper presented to the 3rd Annual Symposium on Graduate Research and Scholarly Projects (GRASP) held at the Hughes Metropolitan Complex, Wichita State University, April 27, 2007.en
dc.descriptionResearch completed at the Department of Physician Assistant, College of Health Professionsen
dc.description.abstractIntroduction: Rheumatoid Arthritis (RA) can be a very debilitating disease, as it causes pain and fatigue associated with inflammation and destruction of multiple joints. Fortunately, newer classes of drugs called tumor necrosis factor inhibitors (TNF-Is) have been proven effective in reducing joint destruction and overall disease severity. However, it is not known which of these TNF-Is is most efficacious. Methods: This retrospective chart review study compares three TNF-Is: Adalimumab (Humira), Infliximab (Remicade), and Etanercept (Enbrel) through a retrospective chart review completed at Arthritis and Rheumatology Clinics of Kansas in Wichita, Kansas. The study analyzed the pain score, fatigue score, and Health Assessment Questionnaire (HAQ) score for 45 women between the ages 35-65 with active RA who were taking one of the three medications mentioned above. Results: One-way ANOVA tests were performed to evaluate the change in pain, fatigue, and HAQ scores for each of the three drugs over one year. The change, or delta, for pain was R=1.673, E=.688, H=-2.136. The delta values for fatigue were all negative except R=.750. The p value for delta HAQ was p=.082. The mean ages for all three drugs were not significantly different. Conclusion: Remicade was the most efficacious drug when considering improvement in pain. The improvement of HAQ scores were not significantly different between the three drugs. A larger sample size and a longer period of time is needed if future research is done to validate research resultsen
dc.format.extent165352 bytes
dc.format.mimetypeapplication/pdf
dc.language.isoen_USen
dc.publisherWichita State University. Graduate School.en
dc.relation.ispartofseriesGRASPen
dc.relation.ispartofseriesv.3en
dc.titleA pilot study and retrospective chart review comparing adalimumab, infliximab, and etanercept in patients with active rheumatoid arthritisen
dc.typeConference paperen


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record